Tirzepatide — lab test, February 2026
COA KVR-2026-5922DF matches Kovera Labs's public record. So this test doesn't rest on our review alone — the lab confirms it too.
WB8MBAZTest results
About this test
Label 40 mg · Lab measured 44.17 mg
110% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 11 mg using the measured mass, against 10 mg on the label — 10% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | KVR-2026-5922DF |
|---|---|
| Portal lookup | ✓ Lab-verified |
| Checked | 31 Jul 2026date taken from the record, not from a logged check |
| Checked by | Peptigrity staff, against the lab's portal |
| PDF vs portal | Kovera Labs's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of Tirzepatide, performed by Kovera Labs on February 11, 2026. Reported purity: 99.604%. Net content: 44.17 mg against 40 mg labeled (110% of label). Tested content exceeds the labeled amount by 10%. Endotoxins: PASS (≤0.5 EU/mL). Heavy metals: Lead, Cadmium, Arsenic, Mercury — all Negative. Batch RB-T2-0825-A. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion